A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Status:
Recruiting
Trial end date:
2024-01-18
Target enrollment:
Participant gender:
Summary
In this study, people with non-small-cell lung cancer (NSCLC), triple-negative breast cancer
(TNBC) and squamous-cell carcinoma of the head and neck (SCCHN) will be treated with TAK-676
and pembrolizumab following radiotherapy. The main aims of this study are to check if people
are getting side effects from these combined treatments and how much TAK-676 people with
these cancers can receive without getting side effects from it.
Participants will receive radiotherapy, then at least 40 hours later will receive
pembrolizumab followed by TAK-676 slowly through a vein (infusion). Participants will receive
an infusion of pembrolizumab at the same dose every 3 weeks. Different small groups of
participants will receive lower to higher doses of TAK-676 on specific days of a 21-day
cycle.